Parkinson disease (PD) and dementia with Lewy bodies (DLB) are characterized by the accumulation of abnormal a-synuclein and ubiquitin in protein aggregates conforming Lewy bodies and Lewy neurites. Ubiquitin C-terminal hydrolase-1 (UCHL-1) disassembles polyubiquitin chains to increase the availability of free monomeric ubiquitin to the ubiquitin proteasome system (UPS) thus favoring protein degradation. Since mutations in the UCHL-1 gene, reducing UPS activity by 50%, have been reported in autosomal dominant PD, and UCHL-1 inhibition results in the formation of a-synuclein aggregates in mesencephalic cultured neurons, the present study was initiated to test UCHL-1 mRNA and protein levels in post-mortem frontal cortex (area 8) of PD and DLB cases, compared with agematched controls. TaqMan PCR assays, and Western blots demonstrated down-regulation of UCHL-1 mRNA and UCHL-1 protein in the cerebral cortex in DLB (either in pure forms, not associated with Alzheimer disease: AD, and in common forms, with accompanying AD changes), but not in PD, when compared with age-matched controls. Interestingly, UCHL-1 mRNA and protein expressions were reduced in the medulla oblongata in the same PD cases. Moreover, UCHL-1 protein was decreased in the substantia nigra in cases with Lewy body pathology. UCHL-1 down-regulation was not associated with reduced protein levels of several proteasomal subunits, including 20SX, 20SY, 19S and 11Sa. Yet UCHL-3 expression was reduced in the cerebral cortex of PD and DLB patients. Together, these observations show reduced UCHL-1 expression as a contributory factor in the abnormal protein aggregation in DLB, and points UCHL-1 as a putative therapeutic target in the treatment of DLB. D
Introduction
Parkinson's disease (PD) and Dementia with Lewy bodies (DLB) are considered a-synucleinopathies because abnormal asynuclein is aggregated into Lewy bodies and Lewy neurites in selected nuclei of the brain stem, spinal cord, autonomic ganglia. In addition, DLB is characterized by the widespread distribution of LBs and a-synuclein-containing neurites in the cerebral cortex (Forno, 1996; Spillantini et al., 1998; Ince et al., 1998; Jellinger and Mizuno, 2003; Ince and McKeith, 2003) . DLB is often accompanied by Alzheimer's disease (AD) and this is considered the common form (DLBc); DLB with minimal hA4-amyloid deposits and no tau pathology characterizes the pure form (DLBp) (Kosaka, 1990 (Kosaka, , 1993 . The reasons of abnormal a-synuclein accumulation in neurons and neuronal processes in Lewy body diseases are not known but several observations, point to the likelihood that the ubiquitin -proteasome system (UPS) is involved in the pathogenesis of PD and DLB (McNaught and Olanow, 2003; McNaught et al., 2003) .
The UPS regulates intracellular protein turnover, and the elimination of misfolded, mutated and damaged proteins (Herschko and Ciechanover, 1998; Glickman and Ciechanover, 2002) . The process is initiated with the conjugation of the target protein to a chain of ubiquitin molecules to be recognized by the 26S proteasome which is composed of the 20S proteasome and the 19S, or PA700, complex. The 20S proteasome contains a 28-subunit catalytic core formed by two outer rings (each with 7 asubunits) and two inner rings (X, Y, each with 7 h-subunits), forming a cylindrical structure. The 19S complex recognizes ubiquitinylated proteins tagged for destruction, and unfolds and inserts the proteins into the core of the 20S proteasome where they are degraded (Tanaka and Tsurumi, 1997; Ciechanover, 1998; Botchler et al., 1999) . In addition to the 19S complex, the 20S proteasome can interact with the 11S activator, or PA28ah complex, forming the PA28 proteasome (Groetrup et al., 1996;  
